NEW YORK, Feb. 3 (Xinhua) -- U.S. drugmaker Pfizer on Tuesday reported fourth-quarter financial results that surpassed analyst expectations, even as demand for its pandemic-era products continued to wane.
The New York-based drugmaker reported fourth-quarter revenue of 17.6 billion U.S. dollars, representing a 3 percent operational decline year over year. Adjusted diluted earnings per share (EPS) for the quarter came in at 0.66 dollars.
For the full year of 2025, Pfizer posted revenue of 62.6 billion dollars and an adjusted diluted EPS of 3.22 dollars, beating the consensus estimates polled by FactSet, which had anticipated revenue of 61.9 billion dollars and earnings of 3.12 dollars per share.
The company's results highlighted the diminishing role of COVID-19 products in its financial performance. In the fourth quarter, revenue for the Comirnaty vaccine plunged 35 percent, while sales of the antiviral treatment Paxlovid sank 70 percent.
However, excluding contributions from the two COVID-19 products, Pfizer's revenues grew 9 percent operationally in the fourth quarter and 6 percent for the full year. "With excellent execution in 2025, we delivered a solid financial performance and strengthened Pfizer's foundation for future growth," Pfizer Chairman and CEO Albert Bourla said in the earnings report.
Key drivers for the non-COVID portfolio included the Prevnar family of vaccines and the migraine medication Nurtec, which Pfizer acquired in 2022. Nurtec surpassed the 1 billion dollar revenue threshold in 2025, solidifying its status as a blockbuster drug.
Pfizer reaffirmed its full-year 2026 guidance, projecting revenues in the range of 59.5 billion to 62.5 billion dollars and adjusted diluted EPS between 2.8 and 3 dollars. The company noted that the guidance does not anticipate any stock buybacks.
"I'm pleased with our solid financial results in 2025. With focused commercial execution, we delivered full-year operational revenue growth of 6 percent for our non-COVID portfolio," said Pfizer CFO David Denton.
